Cargando…

Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial

BACKGROUND: Metabolic syndrome (MetS) comprises a spectrum of clinical phenotypes in which dyslipidemia, dysglycemia and hypertension are clustered and where all share a high level of oxidative stress and an increased risk of cardiovascular disease. This study examines the effect of a nutritional su...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeven, Veronique, Van der Auwera, Anastasia, Van Gaal, Luc, Remmen, Roy, Apers, Sandra, Stalpaert, Michel, Wens, Johan, Hermans, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364089/
https://www.ncbi.nlm.nih.gov/pubmed/25879228
http://dx.doi.org/10.1186/s12906-015-0576-9
_version_ 1782362021867552768
author Verhoeven, Veronique
Van der Auwera, Anastasia
Van Gaal, Luc
Remmen, Roy
Apers, Sandra
Stalpaert, Michel
Wens, Johan
Hermans, Nina
author_facet Verhoeven, Veronique
Van der Auwera, Anastasia
Van Gaal, Luc
Remmen, Roy
Apers, Sandra
Stalpaert, Michel
Wens, Johan
Hermans, Nina
author_sort Verhoeven, Veronique
collection PubMed
description BACKGROUND: Metabolic syndrome (MetS) comprises a spectrum of clinical phenotypes in which dyslipidemia, dysglycemia and hypertension are clustered and where all share a high level of oxidative stress and an increased risk of cardiovascular disease. This study examines the effect of a nutritional supplement combining red yeast rice and olive fruit extract on the lipid profile and on oxidative stress in a population of patients with MetS. METHODS: In a double blind placebo controlled randomized trial, 50 persons with MetS, as defined by the ATPIII criteria, received the study product or placebo for 8 weeks. The study product contained 10.82 mg of monacolins and 9,32 mg of hydroxytyrosol per capsule, and is commercialized as Cholesfytol plus. The primary outcome measure was the difference in LDL reduction between intervention and control groups. Furthermore, differences in changes of CH, HDL, ApoA1, ApoB, HbA1c and oxLDL were measured, as well as side-effects, CK elevation, changes in clinical parameters and in cardiovascular risk. RESULTS: In the intervention group, LDL cholesterol was lowered by 24% whereas it increased by 1% in the control group (p < 0.001). Other effects observed were a change in total cholesterol (−17% in the intervention group vs +2% in the control group, p < 0.001), apolipoprotein B (−15% vs +6%, p < 0.001), and TG (−9% vs + 16%, p = 0.02). Oxidized LDL decreased by 20% vs an increase of 5% in the control group (p < 0.001). Systolic and diastolic arterial blood pressure decreased significantly by 10 mmHg (vs 0% in the control group, p = 0.001) and 7 mmHg (vs 0% in the control group, p = 0.05) respectively. One person in the intervention group, who suffered from Segawa’s syndrome, dropped out because of severe muscle ache. CONCLUSIONS: The combination of active products in this study may be an alternative approach to statins in people who do not need, or cannot or do not want to be treated with chemical statins. Side effects, effects on oxidative stress and on glucose metabolism need to be examined more thoroughly. TRIAL REGISTRATION: Clinicaltrials.gov NCT02065180 (February 2014).
format Online
Article
Text
id pubmed-4364089
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43640892015-03-19 Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial Verhoeven, Veronique Van der Auwera, Anastasia Van Gaal, Luc Remmen, Roy Apers, Sandra Stalpaert, Michel Wens, Johan Hermans, Nina BMC Complement Altern Med Research Article BACKGROUND: Metabolic syndrome (MetS) comprises a spectrum of clinical phenotypes in which dyslipidemia, dysglycemia and hypertension are clustered and where all share a high level of oxidative stress and an increased risk of cardiovascular disease. This study examines the effect of a nutritional supplement combining red yeast rice and olive fruit extract on the lipid profile and on oxidative stress in a population of patients with MetS. METHODS: In a double blind placebo controlled randomized trial, 50 persons with MetS, as defined by the ATPIII criteria, received the study product or placebo for 8 weeks. The study product contained 10.82 mg of monacolins and 9,32 mg of hydroxytyrosol per capsule, and is commercialized as Cholesfytol plus. The primary outcome measure was the difference in LDL reduction between intervention and control groups. Furthermore, differences in changes of CH, HDL, ApoA1, ApoB, HbA1c and oxLDL were measured, as well as side-effects, CK elevation, changes in clinical parameters and in cardiovascular risk. RESULTS: In the intervention group, LDL cholesterol was lowered by 24% whereas it increased by 1% in the control group (p < 0.001). Other effects observed were a change in total cholesterol (−17% in the intervention group vs +2% in the control group, p < 0.001), apolipoprotein B (−15% vs +6%, p < 0.001), and TG (−9% vs + 16%, p = 0.02). Oxidized LDL decreased by 20% vs an increase of 5% in the control group (p < 0.001). Systolic and diastolic arterial blood pressure decreased significantly by 10 mmHg (vs 0% in the control group, p = 0.001) and 7 mmHg (vs 0% in the control group, p = 0.05) respectively. One person in the intervention group, who suffered from Segawa’s syndrome, dropped out because of severe muscle ache. CONCLUSIONS: The combination of active products in this study may be an alternative approach to statins in people who do not need, or cannot or do not want to be treated with chemical statins. Side effects, effects on oxidative stress and on glucose metabolism need to be examined more thoroughly. TRIAL REGISTRATION: Clinicaltrials.gov NCT02065180 (February 2014). BioMed Central 2015-03-10 /pmc/articles/PMC4364089/ /pubmed/25879228 http://dx.doi.org/10.1186/s12906-015-0576-9 Text en © Verhoeven et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Verhoeven, Veronique
Van der Auwera, Anastasia
Van Gaal, Luc
Remmen, Roy
Apers, Sandra
Stalpaert, Michel
Wens, Johan
Hermans, Nina
Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title_full Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title_fullStr Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title_full_unstemmed Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title_short Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
title_sort can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364089/
https://www.ncbi.nlm.nih.gov/pubmed/25879228
http://dx.doi.org/10.1186/s12906-015-0576-9
work_keys_str_mv AT verhoevenveronique canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT vanderauweraanastasia canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT vangaalluc canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT remmenroy canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT aperssandra canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT stalpaertmichel canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT wensjohan canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial
AT hermansnina canredyeastriceandoliveextractimprovelipidprofileandcardiovascularriskinmetabolicsyndromeadoubleblindplacebocontrolledrandomizedtrial